Current HIV Research - Volume 15, Issue 6, 2017

Background: Despite great improvements in prevention over the last years, much has to be done to reduce new human immunodeficiency virus (HIV) infections. Substantial evidence shows that the six-month period of recent HIV infection contributes disproportionately to HIV transmission. Objective: This study aims to investigate knowledge, normative beliefs, and attitudes of people who inject drugs (PWID) regarding recent Read More

Background: New diagnoses of HIV-1 infection among people who inject drugs (PWID) increased significantly during 2011 in Athens. Objective: Our aim was to investigate the patterns of HIV epidemic spread among PWID and to estimate the transmission dynamics for the major local transmission networks (LTNs). Methods: We analyzed sequences from 2,274 HIV-infected subjects sampled in Greece during 01/01/2011- Read More

Background: Immune reconstitution inflammatory syndrome (IRIS) is a major concern when starting highly active anti-retroviral therapy (HAART) in new patients and especially late presenters. This study attempts to identify risk factors for IRIS and investigate whether certain treatment regimens increase the probability of IRIS for patients at risk. Methods: Retrospective single-centre study of HIV patients treated with HAART. Result Read More

Background: Human immunodeficiency virus type-1 (HIV-1) infection leads to acquired immunodeficiency syndrome (AIDS), a severe viral infection that has claimed approximately 658,507 lives in the US between the years 2010-2014. Antiretroviral (ARV) therapy has proven to inhibit HIV-1, but unlike other viral illness, not cure the infection. Objective: Among various Food and Drug Administration (FDA)-approved ARVs, nucleosid Read More

Although HIV/HCV co-infected individuals were historically considered a “difficult to treat” population in the era of Interferon (IFN)-based anti-HCV treatment, the introduction of directacting antivirals, characterized by excellent efficacy and good safety profile, has widely revolutionized the HCV treatment scenario. Recent real life studies reported excellent sustained virological response rates in HIV/HCV coinfected subjects, thus Read More

Background: Vaccine against HIV-1 is not currently available. In present, Virus like particles (VLPs) as effective strategy was used in several vaccine developing. Two conserved sequences; V3 loop of gp120 and the membrane-proximal external region (MPER) of gp41 are dominant sites for vaccine studies. Objective: In this study, we used fusion gene of MPER and V3 to product recombinant VLPs and introduced a novel retro Read More

Background: HIV-1+ long-term nonprogressors (LTNPs) maintain natural control of viral infection. This study sought to identify and characterize HIV- LTNPs series case, regarding the presence of possible host factors that may be associated with this status. Methods: We evaluated the plasma levels of IP-10/IL-8 chemokines, HLA-B alleles, and IL28B rs12979860 polymorphism in 24 LTNPs who presented with infection by differen Read More

Background: Total HIV-DNA load in peripheral blood cell (PBMCs) reflects the global viral reservoir that seems not to be affected by antiretroviral treatment. However, some studies reported a different permeability of different drugs in cellular compartments. Objective: To investigate the relation between the amount of total HIV-1 DNA and different treatment strategies. Methods: Total HIV-1 DNA was quantified by real tim Read More